- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Journal: Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. (Pubmed Central) - Mar 8, 2019 Pertuzumab-based regimens, including THP, resulted in higher pCR rates as compared to ddAC-TH, with the THP regimen associated with the best tolerability among patients with localized HER2+ breast cancer. Given the various neoadjuvant regimens, additional studies are needed to determine optimal treatment sequencing and escalation/de-escalation strategies to personalize neoadjuvant regimens for localized HER2+ breast cancer.
- |||||||||| Trial completion date, Metastases: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Mar 8, 2019
P2/3, N=716, Active, not recruiting, Given the various neoadjuvant regimens, additional studies are needed to determine optimal treatment sequencing and escalation/de-escalation strategies to personalize neoadjuvant regimens for localized HER2+ breast cancer. Trial completion date: Sep 2018 --> May 2019
- |||||||||| Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Mar 1, 2019
P2, N=20, Recruiting, These results are similar to pCR rates seen in trials using HER2-targeted therapy during the taxane phase only of sequential taxane-anthracycline regimens and suggest that we have reached a therapeutic plateau with HER2-targeted therapies combined with chemotherapy in the neoadjuvant setting. Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: May 2016 --> Mar 2017 | Trial primary completion date: Jul 2019 --> Jul 2020
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion date, Trial primary completion date, Metastases: MATEO: Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Feb 20, 2019 P2, N=400, Recruiting, Active, not recruiting --> Completed Trial completion date: Sep 2018 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Apr 2020
- |||||||||| Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
Trial completion date: TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) - Feb 18, 2019 P3, N=500, Active, not recruiting, Trial completion date: Sep 2018 --> Jul 2020 | Trial primary completion date: Sep 2018 --> Apr 2020 Trial completion date: Dec 2019 --> Apr 2020
- |||||||||| Roferon A (recombinant interferon alfa-2a) / Roche
Retrospective data, Review, Journal: Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis. (Pubmed Central) - Dec 14, 2018 For NMIBC, several intravesical therapies are associated with decreased risk of bladder cancer recurrence versus TURBT alone. BCG is the only agent associated with decreased progression risk versus TURBT alone, but may be associated with higher risk of adverse events than other intravesical therapies, indicating trade-offs between potential benefits and harms.
- |||||||||| Review, Journal: Predicting and Preventing Anthracycline-Related Cardiotoxicity. (Pubmed Central) - Nov 29, 2018
Studies are currently under way to test risk-reducing strategies. There remains a critical need to identify patients with childhood cancer at diagnosis (i.e., prior to anthracycline exposure) such that noncardiotoxic therapies can be contemplated.
- |||||||||| Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: NeoToc: Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer (clinicaltrials.gov) - Oct 9, 2018
P2, N=80, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Apr 2020 | Trial primary completion date: Sep 2018 --> Mar 2019
- |||||||||| Trial completion date, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Oct 1, 2018
P2, N=1460, Recruiting, Recruiting --> Active, not recruiting Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2019 --> Dec 2021
- |||||||||| Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
Enrollment closed: TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) - Sep 25, 2018 P3, N=500, Active, not recruiting, Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Dec 2018 Recruiting --> Active, not recruiting
- |||||||||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Real-world evidence, Real-world: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (clinicaltrials.gov) - Sep 19, 2018 P4, N=260, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Mar 2018
- |||||||||| ifosfamide / Generic mfg., epirubicin / Generic mfg., sorafenib / Generic mfg.
Trial completion, Surgery: Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 7, 2018 P1, N=18, Completed, Recruiting --> Completed | Trial primary completion date: Jan 2018 --> May 2018 Active, not recruiting --> Completed
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Aug 29, 2018 P2, N=401, Active, not recruiting, Trial primary completion date: Sep 2017 --> Sep 2019 Trial completion date: Dec 2020 --> Aug 2020
- |||||||||| Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 (clinicaltrials.gov) - Aug 20, 2018
P2, N=60, Recruiting, Trial completion date: Dec 2020 --> Aug 2020 Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Mar 2033 | Initiation date: Jan 2018 --> Apr 2018 | Trial primary completion date: Dec 2027 --> Mar 2028
|